CPHI Japan 2023 Spotlights China’s Impact on APAC Biopharma
As the biopharma landscape in the Asia-Pacific (APAC) region undergoes significant transformation, CPHI Japan 2023 will delve into the driving factors behind these changes. The event, taking place from April 19-21, will feature a keynote address by Ian Haydock, Editor-In-Chief, Insights, Asia-Pacific at Citeline, discussing China’s increasing influence on the region’s biopharma innovation, manufacturing, and outsourcing strategies.
The event will celebrate its 20th anniversary with an array of special events, including an award ceremony recognizing the pivotal role of companies in the development of Japan’s thriving pharmaceutical industry. CPHI Japan 2023 is set to attract 7,000 executives from 95 countries, indicating a return to pre-pandemic levels of engagement.
With China’s share of global R&D in new drugs and vaccines reaching 24%, the country’s biopharma growth is increasingly affecting the APAC region. This surge has led to the emergence of new distribution channels and regional manufacturing hubs, particularly in Southeast Asia and Japan, which China is now targeting due to recent setbacks in the US market.
Japan’s innovation landscape remains strong, albeit with modest growth, as drug pricing systems continue to challenge research-based multinationals operating in the country. The APAC biopharma sector is characterized by a diverse array of smaller innovators, fostering a dynamic supply side with numerous supply partners.